EP4360629A4 - PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS - Google Patents
PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS Download PDFInfo
- Publication number
- EP4360629A4 EP4360629A4 EP22828825.4A EP22828825A EP4360629A4 EP 4360629 A4 EP4360629 A4 EP 4360629A4 EP 22828825 A EP22828825 A EP 22828825A EP 4360629 A4 EP4360629 A4 EP 4360629A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- management
- treatment
- pharmaceutical composition
- composition containing
- rna virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title 1
- 208000009341 RNA Virus Infections Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210083385 | 2021-06-25 | ||
| KR1020220077063A KR102871928B1 (en) | 2021-06-25 | 2022-06-23 | Pharmaceutical composition containing lipolytic enzyme inhibitors for preventing or treating RNA virus infection |
| PCT/KR2022/009041 WO2022270978A1 (en) | 2021-06-25 | 2022-06-24 | Pharmaceutical composition comprising lipase inhibitor for treatment or treatment of rna viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4360629A1 EP4360629A1 (en) | 2024-05-01 |
| EP4360629A4 true EP4360629A4 (en) | 2024-11-06 |
Family
ID=84544668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22828825.4A Pending EP4360629A4 (en) | 2021-06-25 | 2022-06-24 | PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20240285557A1 (en) |
| EP (1) | EP4360629A4 (en) |
| WO (1) | WO2022270978A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019104686A (en) * | 2017-12-08 | 2019-06-27 | キッコーマン株式会社 | Anti-influenza virus agent and composition containing the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130210883A1 (en) * | 2010-05-21 | 2013-08-15 | Johannes Grillari | Lipase inhibitors |
| EP2627334B1 (en) * | 2010-10-15 | 2015-04-29 | Biocryst Pharmaceuticals, Inc. | Compositions for use in the treatment of viral infections |
| PL3917140T3 (en) | 2012-01-19 | 2023-12-04 | Vid Scale, Inc. | Method and apparatus for signaling and construction of video coding reference picture lists |
| US20180256623A1 (en) * | 2015-09-16 | 2018-09-13 | University Of Virginia Patent Foundation | Compositions and method for regulating adipose tissue lipolysis, insulin-resistance, and hyperglycemia |
| KR102561804B1 (en) | 2020-12-01 | 2023-07-31 | 주식회사 글로벌테크놀로지 | Backlight apparatus for display, current deviation compensation method and compensation circuit of the backlight apparatus |
-
2022
- 2022-06-24 US US18/572,480 patent/US20240285557A1/en active Pending
- 2022-06-24 WO PCT/KR2022/009041 patent/WO2022270978A1/en not_active Ceased
- 2022-06-24 EP EP22828825.4A patent/EP4360629A4/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019104686A (en) * | 2017-12-08 | 2019-06-27 | キッコーマン株式会社 | Anti-influenza virus agent and composition containing the same |
Non-Patent Citations (4)
| Title |
|---|
| LAUFMAN ORLY ET AL: "Viral Generated Inter-Organelle Contacts Redirect Lipid Flux for Genome Replication", CELL, ELSEVIER, AMSTERDAM NL, vol. 178, no. 2, 13 June 2019 (2019-06-13), pages 275, XP085739926, ISSN: 0092-8674, [retrieved on 20190613], DOI: 10.1016/J.CELL.2019.05.030 * |
| NITIN A LUNAGARIYA ET AL: "Review article: INHIBITORS OF PANCREATIC LIPASE: STATE OF THE ART AND CLINICAL PERSPECTIVES", EXCLI JOURNAL, 22 August 2014 (2014-08-22), pages 897 - 921, XP055739962, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464291/pdf/EXCLI-13-897.pdf> * |
| See also references of WO2022270978A1 * |
| TANNER JEROME E. ET AL: "The Fatty Acid Lipid Metabolism Nexus in COVID-19", VIRUSES, vol. 13, no. 1, 11 January 2021 (2021-01-11), CH, XP093206734, ISSN: 1999-4915, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826519/pdf/viruses-13-00090.pdf> DOI: 10.3390/v13010090 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4360629A1 (en) | 2024-05-01 |
| WO2022270978A1 (en) | 2022-12-29 |
| US20240285557A1 (en) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4143176A4 (en) | SARS-COV-2 INHIBITORS WITH COVALENT MODIFICATIONS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | |
| EP4157272C0 (en) | Remdesivir for the treatment of viral infections | |
| EP4175629A4 (en) | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| EP3900717C0 (en) | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRUS DISEASES | |
| EP4426682A4 (en) | SARS-CoV-2 inhibitors for the treatment of coronavirus infections | |
| EP4438048A4 (en) | Pharmaceutical composition for the treatment or prevention of T-cell-related diseases | |
| EP4000609A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES | |
| EP4151227A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | |
| EP4419504A4 (en) | KDM1A inhibitors for the treatment of diseases | |
| EP3620457A4 (en) | PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE | |
| EP3955908C0 (en) | NOVEL MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | |
| EP4142728C0 (en) | 6'-METHOXYCINCHONAN-9-OLS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | |
| EP4125893A4 (en) | TECHNOLOGIES FOR THE PREVENTION OR TREATMENT OF INFECTIONS | |
| EP4431098A4 (en) | Pharmaceutical composition for the treatment of Alport syndrome | |
| EP4382123A4 (en) | Pharmaceutical composition for the treatment of small cell lung cancer | |
| EP4285910A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NERVE INFECTIONS WITH ELEUTHEROSIDE B AS ACTIVE INGREDIENT | |
| EP4360629A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS | |
| EP3919063A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF LYSOSOMIC STORAGE DISEASES | |
| EP4452295A4 (en) | Pharmaceutical composition for the treatment of viral infections | |
| EP4203954A4 (en) | GLUCOSIDASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS | |
| EP4582087A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LYMPHOMAS | |
| EP4149451A4 (en) | CYSTEAMINE FOR THE TREATMENT OF SARS-COV-2 INFECTION | |
| EP4306133A4 (en) | Composition for the administration of double-stranded oligonucleotide structures using an ultrasonic nebulizer for the prevention or treatment of viral infections | |
| EP4351546A4 (en) | HOST-DIRECTED DRUG COMBINATIONS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| EP4570251A4 (en) | Composition for the treatment or prevention of kidney diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20231213 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20241008 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/706 20060101ALI20241001BHEP Ipc: A61K 31/215 20060101ALI20241001BHEP Ipc: A61P 31/14 20060101ALI20241001BHEP Ipc: A61K 31/4245 20060101ALI20241001BHEP Ipc: A61K 31/5375 20060101ALI20241001BHEP Ipc: A61K 31/40 20060101ALI20241001BHEP Ipc: A61K 31/17 20060101AFI20241001BHEP |